Drugs / pentavalent reassortant rotavirus attenuated live vaccine
pentavalent reassortant rotavirus attenuated live vaccine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT06967272 Comparator | Jan 2025 → Jun 2026 overdue | Rotavirus infection | Sinovac Life Sciences Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pentavalent reassortant rotavirus attenuated live vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06967272 ↗ |
| Route | Oral | “The controlled vaccine three doses administered orally” NCT06967272 ↗ |